Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Phase 3
Suspended
- Conditions
- Glioblastoma Multiforme
- Interventions
- Biological: PlaceboBiological: ICT-107
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Precision Life Sciences Group
- Target Recruit Count
- 234
- Registration Number
- NCT02546102
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธCity of Hope Cancer Center, Duarte, California, United States
๐บ๐ธPiedmont Hospital, Atlanta, Georgia, United States
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Phase 1
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- Biological: ICT-121 DC vaccine
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Precision Life Sciences Group
- Target Recruit Count
- 20
- Registration Number
- NCT02049489
- Locations
- ๐บ๐ธ
UC San Diego Moores Cancer Center, La Jolla, California, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธPenn State Hershey Neuroscience Institute, Hershey, Pennsylvania, United States
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- Biological: ICT-107Biological: Placebo DC
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Precision Life Sciences Group
- Target Recruit Count
- 124
- Registration Number
- NCT01280552
- Locations
- ๐บ๐ธ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Virginia Health System, Charlottesville, Virginia, United States
๐บ๐ธNYU Clinical Cancer Center, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath